Accrued Liabilities - Fujian Cosunter Pharmaceutical Co Ltd (SZSE:300436) - Alpha Spread
F

Fujian Cosunter Pharmaceutical Co Ltd
SZSE:300436

Watchlist Manager
Fujian Cosunter Pharmaceutical Co Ltd
SZSE:300436
Watchlist
Price: 17.97 CNY -2.5% Market Closed
Market Cap: 2.9B CNY
Have any thoughts about
Fujian Cosunter Pharmaceutical Co Ltd?
Write Note

Fujian Cosunter Pharmaceutical Co Ltd
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Fujian Cosunter Pharmaceutical Co Ltd
Accrued Liabilities Peer Comparison

Comparables:
H
3692
600436
600276
000538
S
688506

Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
F
Fujian Cosunter Pharmaceutical Co Ltd
SZSE:300436
Accrued Liabilities
ÂĄ37.3m
CAGR 3-Years
102%
CAGR 5-Years
39%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Accrued Liabilities
ÂĄ2B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Accrued Liabilities
ÂĄ620.1m
CAGR 3-Years
8%
CAGR 5-Years
39%
CAGR 10-Years
35%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Accrued Liabilities
ÂĄ128.5m
CAGR 3-Years
10%
CAGR 5-Years
9%
CAGR 10-Years
8%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Accrued Liabilities
ÂĄ1.5B
CAGR 3-Years
48%
CAGR 5-Years
46%
CAGR 10-Years
59%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Accrued Liabilities
ÂĄ146m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Fujian Cosunter Pharmaceutical Co Ltd's Accrued Liabilities?
Accrued Liabilities
37.3m CNY

Based on the financial report for Mar 31, 2024, Fujian Cosunter Pharmaceutical Co Ltd's Accrued Liabilities amounts to 37.3m CNY.

What is Fujian Cosunter Pharmaceutical Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
39%

Over the last year, the Accrued Liabilities growth was 507%. The average annual Accrued Liabilities growth rates for Fujian Cosunter Pharmaceutical Co Ltd have been 102% over the past three years , 39% over the past five years .

Back to Top